



Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of
malaria RDTs: Round 1 (2008)

Malaria Rapid Diagnostic Test Performance

Results of WHO product testing of malaria RDTs: Round 1 (2008)



Special Programme for Research & Training
in Tropical Diseases (TDR) sponsored by
UNICEF/UNDP/World Bank/WHO

WHO Library Cataloguing-in-Publication Data :

Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 1 (2008).

1.Malaria - diagnosis. 2.Antimalarials - therapeutic use. 3.Malaria - drug therapy. 4.Diagnostic tests, Routine. 5.Reagent kits, Diagnostic - utilization.. 6.Sensitivity and specificity. I.UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. II.Centers for Disease Control (U.S.). III.Foundation for Innovative New Diagnostics.

ISBN 978 92 4 159807 1

(NLM classification: WC 750)

Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2009

All rights reserved.

The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated. A copy of any resulting product with such content should be sent to TDR, World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland. TDR is a World Health Organization (WHO) executed UNICEF/UNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

This information product is not for sale. The use of any information or content whatsoever from it for publicity or advertising, or for any commercial or income-generating purpose, is strictly prohibited. No elements of this information product, in part or in whole, may be used to promote any specific individual, entity or product, in any manner whatsoever.

The designations employed and the presentation of material in this health information product, including maps and other illustrative materials, do not imply the expression of any opinion whatsoever on the part of WHO, including TDR, the authors or any parties cooperating in the production, concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delineation of frontiers and borders.

Mention or depiction of any specific product or commercial enterprise does not imply endorsement or recommendation by WHO, including TDR, the authors or any parties cooperating in the production, in preference to others of a similar nature not mentioned or depicted.

The views expressed in this health information product are those of the authors and do not necessarily reflect those of WHO, including TDR. WHO, including TDR, and the authors of this health information product make no warranties or representations regarding the content, presentation, appearance, completeness or accuracy in any medium and shall not be held liable for any damages whatsoever as a result of its use or application. WHO, including TDR, reserves the right to make updates and changes without notice and accepts no liability for any errors or omissions in this regard. Any alteration to the original content brought about by display or access through different media is not the responsibility of WHO, including TDR, or the authors. WHO, including TDR, and the authors accept no responsibility whatsoever for any inaccurate advice or information that is provided by sources reached via linkages or references to this health information product.

Design by paprika-annecy.com

Printed in France

Contents

Acknowledgements	>	V
Abbreviations	>	VI
1. EXECUTIVE SUMMARY	>	1
1.1. Introduction	>	1
1.2. The WHO Product Testing Programme	>	1
1.3. Results of the evaluation	>	1
1.4. Summary of outcomes	>	3
1.5. Use of these results	>	3
2. BACKGROUND	>	3
3. OBJECTIVES	>	5
4. DATA MANAGEMENT	>	6
4.1. Test selection	>	6
4.2. Outline of the Product Testing Protocol	>	7
4.3. Evaluation panels	>	7
4.4. RDT registration	>	9
4.5. Specimen panel registration	>	9
4.6. Test phases	>	9
4.7. Performing rapid tests	>	10
4.8. Interpretation of results	>	10
5. MATERIALS AND METHODS	>	11
6. QUALITY ASSURANCE	>	11
7. ETHICAL CONSIDERATIONS	>	12
8. DATA ANALYSIS	>	12
8.1. Defining sensitivity and specificity/ detection and false positive rates	>	12
8.2. False-positives	>	12
8.2.1. Incorrect species identification	>	12
8.2.2. False-positives from <i>Plasmodium</i> - negative samples	>	13
8.3. Band intensity	>	13
8.4. Lot agreement	>	13
8.5. Reader variability	>	13
8.6. Invalid tests	>	13
8.7. Heat (thermal) stability	>	13
9. LABORATORY VERSUS FIELD-BASED MALARIA RDT EVALUATIONS	>	13
10. RESULTS	>	14
10.1. Summary	>	14
10.2. Phase 1 - <i>P. falciparum</i> culture panel	>	20

10.3. Phase 2 - Wild type <i>P. falciparum</i> and <i>P. vivax</i> and <i>Plasmodium</i> spp. negative samples	>	21
10.3.1. <i>P. falciparum</i> detection rate	>	21
10.3.2. <i>P. vivax</i> detection rate	>	22
10.3.3. Combined Detection of <i>P. falciparum</i> and <i>P. vivax</i>	>	22
10.3.4. <i>P. falciparum</i> and <i>P. vivax</i> positivity rate	>	23
10.3.5. Band intensity	>	25
10.3.6. False positive rates	>	25
10.3.7. Inter-reader variability	>	29
11. HEAT STABILITY	>	32
11.1. <i>P. falciparum</i> test lines	>	32
11.2. Pan test lines	>	34
12. EASE OF USE DESCRIPTION	>	35
13. DISCUSSION OF KEY FINDINGS	>	38
13.1. Parasite detection and its relationship to sensitivity	>	38
13.2. False-positive rate and specificity	>	39
13.3. Heat (thermal) stability	>	39
13.4. Ease of use description	>	40
13.5. Inter-lot variability	>	40
13.6. Inter-reader variability	>	40
13.7. Target antigens and species	>	41
14. ADDITIONAL MEASURES TO ENSURE QUALITY AND UTILITY OF RDT TESTING	>	41
14.1. Beyond procurement	>	41
14.2. Lot testing	>	42
15. CONCLUSIONS	>	42
16. REFERENCES	>	43
ANNEXES	>	45
Annex 1: Characteristics of rapid malaria malaria tests in the evaluation	>	46
Annex 2: Malaria RDT guide to results interpretation	>	53
Annex 3: Phase 1 results	>	58
Annex 4: Phase 2 results	>	63
Annex 5: Example algorithm for selecting a malaria RDT	>	90
Annex 6: Introducing RDT-based malaria diagnosis into national programmes	>	92

FIGURES

- Figure E1: Summary performance of malaria RDTs against blood samples containing wild type *P. falciparum* at low (200) and high (2000 or 5000) parasite densities (parasites/ μ l) and malaria-negative samples.
- Figure 1: Mode of action of antigen-detecting malaria RDTs
- Figure 2: Network of specimen collection, characterization and testing sites
- Figure 3: Malaria RDT Product Testing Overview
- Figure 4a: Origin of *P. falciparum* wild type samples
- Figure 4b: Origin of *P. vivax* wild type samples
- Figure 5: Testing procedure for Product A against a sample density of 2000 or 5000 parasites/ μ l
- Figure 6: Testing procedure for Product A against a sample density of 200 parasites/ μ l
- Figure 7: Phase 1 *P. falciparum* detection rate of malaria RDTs at low (200) and high (2000 or 5000) parasite densities (parasites/ μ l) according to target antigen type (HRP2 or pLDH)
- Figure 8: Phase 2 *P. falciparum* detection rate of malaria RDTs at low (200) and high (2000 or 5000) parasite density (parasites/ μ l) according to target antigen type (HRP2 or pLDH)
- Figure 9: Phase 2 *P. vivax* detection rate of malaria RDTs at low (200) and high (2000 or 5000) parasite densities (parasites/ μ l) according to target antigen type (aldolase, pLDH, aldolase + pLDH)
- Figure 10: Phase 2 wild type *P. falciparum* detection rate and positivity rate at 200 parasites/ μ l
- Figure 11: Phase 2 wild type *P. vivax* detection rate and positivity rate at 200 parasites/ μ l
- Figure 12: *P. falciparum* (*P. falciparum* test line) false positive rate against clean negative samples
- Figure 13: *P. falciparum* (*P. falciparum* test line) false positive rate against *Plasmodium* spp. negative samples containing potentially cross-reacting blood immunological abnormalities or infectious pathogens
- Figure 14: *Plasmodium* spp. (*pan* or *P. vivax* test line) false positive rate against clean negatives
- Figure 15: *Plasmodium* spp. (*pan* or *P. vivax* test line) false positive rate against *Plasmodium* spp. negative samples containing potentially cross-reacting blood immunological abnormalities or infectious pathogens
- Figure 16: *P. falciparum* false positive rate versus *P. falciparum* detection rate at low (200) parasite density (parasites/ μ l)
- Figure 17: *P. vivax* false positive rate versus *P. vivax* detection rate at low (200) parasite density (parasites/ μ l)
- Figure 18: Wild type *P. falciparum* detection rate according to first and second readings at 200 parasites/ μ l
- Figure 19: Wild type *P. vivax* detection rate according to first and second readings at 200 parasites/ μ l
- Figure 20: Heat stability of *P. falciparum* specific (HRP2) test line of *P. falciparum* only tests against a low density *P. falciparum* sample (200 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 21: Heat stability of *P. falciparum* specific (HRP2) test line of *P. falciparum* tests against a high density *P. falciparum* sample (2000 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 22: Heat stability of *P. falciparum* specific (HRP2) test line in combination tests against a low density *P. falciparum* sample (200 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 23: Heat stability of *P. falciparum* specific (HRP2) test line in combination tests against a high density *P. falciparum* sample (2000 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.

- Figure 24: Heat stability of pan-line of pan-specific tests against a low density *P. falciparum* sample (200 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 25: Heat stability of pan-line of pan-specific tests against a high density *P. falciparum* sample (2000 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 26: Heat stability of pan-line of combination tests against a low density *P. falciparum* sample (200 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 27: Heat stability of pan-line of combination tests against a high density *P. falciparum* sample (2000 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 28: Heat stability of pan-line of pan-specific tests only against a low density *P. falciparum* sample (200 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure 29: Heat stability of pan-line of pan-specific tests only against a high density *P. falciparum* sample (2000 parasites/ μ l). Positivity rate at baseline, and after 60 days incubation.
- Figure A6.1: Example malaria RDT implementation budget

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29134

